IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500, NDX | P/E | 41.20 | EPS (ttm) | 14.24 | Insider Own | 0.91% | Shs Outstand | 78.88M | Perf Week | 4.94% |
| Market Cap | 46.28B | Forward P/E | 35.05 | EPS next Y | 16.74 | Insider Trans | -6.42% | Shs Float | 78.58M | Perf Month | 5.03% |
| Enterprise Value | 47.05B | PEG | 2.33 | EPS next Q | - | Inst Own | 66.43% | Short Float | 2.67% | Perf Quarter | 2.53% |
| Income | 1.12B | P/S | 10.16 | EPS this Y | 8.62% | Inst Trans | - | Short Ratio | 3.21 | Perf Half Y | -8.84% |
| Sales | 4.55B | P/B | 29.14 | EPS next Y | 13.65% | ROA | 33.11% | Short Interest | 2.10M | Perf YTD | -13.28% |
| Book/sh | - | P/C | 34.36 | EPS next 5Y | 14.84% | ROE | 71.96% | 52W High | 787.41 -23.81% | Perf Year | -6.01% |
| Cash/sh | - | P/FCF | 37.01 | EPS past 3/5Y | 17.66% 14.28% | ROIC | 41.33% | 52W Low | 530.25 13.14% | Perf 3Y | 13.00% |
| Dividend Est. | - | EV/EBITDA | 29.84 | Sales past 3/5Y | 8.53% 9.72% | Gross Margin | 62.45% | Volatility | 4.19% 3.17% | Perf 5Y | -13.54% |
| Dividend TTM | - | EV/Sales | 10.33 | EPS Y/Y TTM | 27.09% | Oper. Margin | 32.03% | ATR (14) | 20.13 | Perf 10Y | 529.41% |
| Dividend Ex-Date | - | Quick Ratio | 0.87 | Sales Y/Y TTM | 14.06% | Profit Margin | 25.03% | RSI (14) | 59.76 | Recom | 2.48 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.17 | EPS Q/Q | 17.23% | SMA20 | 4.01% | Beta | 1.53 | Target Price | 685.00 |
| Payout | 0.00% | Debt/Eq | 0.60 | Sales Q/Q | 14.33% | SMA50 | 4.77% | Rel Volume | 0.87 | Prev Close | 586.67 |
| Employees | 11,000 | LT Debt/Eq | 0.36 | Earnings | Nov 02 | SMA200 | -5.24% | Avg Volume | 667.83K | Price | 599.93 |
| IPO Date | Jun 21, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.76% 2.00% | Net Debt/EBITDA | 0.49 | Volume | 583,351 | Change | 2.26% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-27-26 | Reiterated | UBS | Neutral | $640 → $620 |
| Apr-28-26 | Reiterated | UBS | Neutral | $730 → $640 |
| Feb-09-26 | Reiterated | Piper Sandler | Neutral | $750 |
| Feb-05-26 | Reiterated | Barclays | Overweight | $850 → $800 |
| Feb-03-26 | Reiterated | UBS | Neutral | $750 → $730 |
| Feb-03-26 | Reiterated | BTIG | Buy | $830 → $800 |
| Dec-08-25 | Initiated | Barclays | Overweight | $590 → $850 |
| Nov-04-25 | Reiterated | Jefferies | $830 | |
| Nov-04-25 | Reiterated | Morgan Stanley | Overweight | $722 → $805 |
| Nov-04-25 | Reiterated | BTIG | Buy | $785 → $830 |
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,554 | 4,304 | 3,898 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,709 | 1,644 | 1,519 | — | — | — | — | — | — | |
| Gross Profit | 2,843 | 2,660 | 2,379 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,123 | 1,048 | 1,031 | — | — | — | — | — | — | |
| Research and Development | 261 | 251 | 220 | — | — | — | — | — | — | |
| Other Operating Expense | 2 | 1 | 0 | — | — | — | — | — | — | |
| Operating Income | 1,460 | 1,360 | 1,128 | — | — | — | — | — | — | |
| Interest Expense | 40 | 38 | 31 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 2 | 13 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,424 | 1,324 | 1,110 | — | — | — | — | — | — | |
| Income Taxes | 285 | 265 | 222 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,139 | 1,059 | 888 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,139 | 1,059 | 888 | — | — | — | — | — | — | |
| Net Income | 1,139 | 1,059 | 888 | — | — | — | — | — | — | |
| EPS (Recurring) | 14.24 | 13.17 | 10.77 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 14.24 | 13.17 | 10.77 | — | — | — | — | — | — | |
| EPS (Diluted) | 14.12 | 13.08 | 10.67 | — | — | — | — | — | — | |
| EBITDA | 1,576 | 1,469 | 1,276 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 42.49 | 51.72 | 38.75 | — | — | — | — | — | — | |
| Price To Sales Ratio | 10.54 | 12.57 | 8.70 | — | — | — | — | — | — | |
| Gross Margin | 62.43 | 61.80 | 61.03 | — | — | — | — | — | — | |
| Operating Margin | 32.06 | 31.60 | 28.94 | — | — | — | — | — | — | |
| Net Margin | 25.01 | 24.61 | 22.78 | — | — | — | — | — | — | |
| Shares Outstanding | 80 | 80 | 82 | — | — | — | — | — | — | |
| Market Capitalization | 47,994 | 54,122 | 33,902 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| FENNELL GEORGE | Executive Vice President | Jun 01 '26 | Option Exercise | 0.00 | 639 | 0 | 10,717 | Jun 02 |
| Vandebroek Sophie V. | Director | May 07 '26 | Option Exercise | 0.00 | 257 | 0 | 905 | May 11 |
| SZOSTAK M ANNE | Director | May 07 '26 | Option Exercise | 0.00 | 257 | 0 | 519 | May 11 |
| Peacock Karen | Director | May 07 '26 | Option Exercise | 0.00 | 101 | 0 | 102 | May 11 |
| Kingsley Lawrence D | Director | May 07 '26 | Option Exercise | 0.00 | 339 | 0 | 9,568 | May 11 |
| JUNIUS DANIEL M | Director | May 07 '26 | Option Exercise | 0.00 | 257 | 0 | 3,561 | May 11 |
| HOOLEY JOSEPH L | Director | May 07 '26 | Option Exercise | 0.00 | 158 | 0 | 276 | May 11 |
| Underberg Sharon E. | EVP, GC & Corporate Secretary | Mar 03 '26 | Option Exercise | 505.53 | 197 | 99,589 | 7,138 | Mar 05 |
| Hunt Nimrata | Executive Vice President | Mar 03 '26 | Sale | 634.57 | 1,758 | 1,115,577 | 18,141 | Mar 05 |
| MAZELSKY JONATHAN JAY | President and CEO | Feb 27 '26 | Option Exercise | 505.53 | 197 | 99,589 | 83,803 | Mar 02 |
| MAZELSKY JONATHAN JAY | President and CEO | Feb 26 '26 | Sale | 657.55 | 23,326 | 15,338,082 | 83,606 | Mar 02 |
| MAZELSKY JONATHAN JAY | President and CEO | Feb 26 '26 | Option Exercise | 141.60 | 23,326 | 3,302,962 | 106,932 | Mar 02 |
| Hunt Nimrata | Executive Vice President | Feb 26 '26 | Sale | 661.54 | 2,693 | 1,781,531 | 19,899 | Feb 27 |
| Erickson Michael G | Executive Vice President | Feb 19 '26 | Option Exercise | 227.83 | 2,399 | 546,556 | 15,092 | Feb 19 |
| Vandebroek Sophie V. | Director | Feb 17 '26 | Sale | 628.62 | 1,464 | 920,293 | 648 | Feb 19 |